Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2024 | May 03, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-36362 | |
Entity Registrant Name | BioLife Solutions, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3076866 | |
Entity Address, Address Line One | 3303 Monte Villa Parkway, Suite 310 | |
Entity Address, City or Town | Bothell | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98021 | |
City Area Code | 425 | |
Local Phone Number | 402-1400 | |
Title of 12(b) Security | Common stock, par value $0.001 per share | |
Trading Symbol | BLFS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 46,030,886 | |
Entity Central Index Key | 0000834365 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Unaudited Condensed Consolidate
Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 29,694 | $ 35,407 |
Restricted cash | 31 | 31 |
Available-for-sale securities, current portion | 15,579 | 16,288 |
Accounts receivable, trade, net of allowance for credit losses of $1,745 and $1,710 as of March 31, 2024 and December 31, 2023, respectively | 18,574 | 18,657 |
Inventories | 43,414 | 43,456 |
Prepaid expenses and other current assets | 4,408 | 6,765 |
Total current assets | 111,700 | 120,604 |
Assets held for rent, net | 6,904 | 7,713 |
Property and equipment, net | 21,042 | 21,077 |
Operating lease right-of-use assets, net | 10,779 | 11,446 |
Financing lease right-of-use assets, net | 65 | 94 |
Long-term deposits and other assets | 245 | 273 |
Available-for-sale securities, long-term | 822 | 548 |
Equity investments | 5,069 | 5,069 |
Intangible assets, net | 20,235 | 21,149 |
Goodwill | 224,741 | 224,741 |
Total assets | 401,602 | 412,714 |
Current liabilities: | ||
Accounts payable | 4,984 | 6,940 |
Accrued expenses and other current liabilities | 8,863 | 11,932 |
Sales taxes payable | 5,395 | 5,442 |
Warranty liability | 7,800 | 7,858 |
Lease liabilities, operating, current portion | 2,645 | 2,797 |
Lease liabilities, financing, current portion | 352 | 376 |
Debt, current portion | 8,619 | 6,833 |
Total current liabilities | 38,658 | 42,178 |
Lease liabilities, operating, long-term | 12,579 | 13,205 |
Lease liabilities, financing, long-term | 1,086 | 1,169 |
Debt, long-term | 15,681 | 18,311 |
Deferred tax liabilities | 193 | 188 |
Total liabilities | 68,197 | 75,051 |
Commitments and contingencies (Note 12) | ||
Shareholders’ equity: | ||
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 150,000,000 shares authorized, 45,689,583 and 45,167,225 shares issued and outstanding, respectively, as of March 31, 2024 and December 31, 2023 | 46 | 45 |
Additional paid-in capital | 659,063 | 652,880 |
Accumulated other comprehensive loss, net of taxes | (566) | (345) |
Accumulated deficit | (325,138) | (314,917) |
Total shareholders’ equity | 333,405 | 337,663 |
Total liabilities and shareholders’ equity | $ 401,602 | $ 412,714 |
Unaudited Condensed Consolida_2
Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Allowance for doubtful accounts | $ 1,745 | $ 1,710 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, shares issued (in shares) | 45,689,583 | 45,167,225 |
Common stock, shares outstanding (in shares) | 45,689,583 | 45,167,225 |
Series A Preferred Stock | ||
Preferred stock, shares designated (in shares) | 4,250 | 4,250 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Unaudited Condensed Consolida_3
Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Total product, rental, and service revenue | $ 31,727 | $ 37,703 |
Costs and operating expenses: | ||
General and administrative | 12,934 | 14,842 |
Sales and marketing | 5,070 | 6,471 |
Research and development | 3,534 | 4,152 |
Intangible asset amortization | 914 | 1,459 |
Acquisition costs | 237 | 0 |
Change in fair value of contingent consideration | 0 | 720 |
Total operating expenses | 41,855 | 51,308 |
Operating loss | (10,128) | (13,605) |
Other income (expense): | ||
Interest expense, net | (207) | (411) |
Other income | 245 | 394 |
Total other income (expense), net | 38 | (17) |
Loss before income tax expense | (10,090) | (13,622) |
Income tax expense | (131) | (92) |
Net loss | (10,221) | (13,714) |
Net loss attributable to common shareholders: | ||
Basic | (10,221) | (13,714) |
Diluted | $ (10,221) | $ (13,714) |
Net loss per share attributable to common shareholders: | ||
Basic (in dollars per share) | $ (0.22) | $ (0.32) |
Diluted (in dollars per share) | $ (0.22) | $ (0.32) |
Weighted average shares used to compute loss per share attributable to common shareholders: | ||
Basic (in shares) | 45,432,426 | 43,027,612 |
Diluted (in shares) | 45,432,426 | 43,027,612 |
Product revenue | ||
Total product, rental, and service revenue | $ 24,803 | $ 31,593 |
Costs and operating expenses: | ||
Cost of goods and services sold (exclusive of intangible assets amortization) | 14,384 | 18,397 |
Service revenue | ||
Total product, rental, and service revenue | 5,088 | 4,471 |
Costs and operating expenses: | ||
Cost of goods and services sold (exclusive of intangible assets amortization) | 3,519 | 3,891 |
Rental revenue | ||
Total product, rental, and service revenue | 1,836 | 1,639 |
Costs and operating expenses: | ||
Cost of goods and services sold (exclusive of intangible assets amortization) | $ 1,263 | $ 1,376 |
Unaudited Condensed Consolida_4
Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (10,221) | $ (13,714) |
Other comprehensive income (loss): | ||
Foreign currency translation adjustment, net of tax | (203) | 106 |
Unrealized (loss) gain on available-for-sale securities, net of tax | (18) | 39 |
Comprehensive loss | $ (10,442) | $ (13,569) |
Unaudited Condensed Consolida_5
Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands | Total | Series A Preferred Stock | Preferred Stock Series A Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit |
Beginning balance, preferred stock, shares outstanding (in shares) at Dec. 31, 2022 | 0 | ||||||
Beginning balance at Dec. 31, 2022 | $ 364,188 | $ 0 | $ 43 | $ 611,739 | $ (679) | $ (246,915) | |
Beginning balance, common stock, shares outstanding (in shares) at Dec. 31, 2022 | 42,832,231 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Stock-based compensation | 7,363 | 7,363 | |||||
Stock option exercises (in shares) | 80,938 | ||||||
Stock option exercises | 125 | 125 | |||||
Stock issued - on vested RSAs (in shares) | 376,800 | ||||||
Foreign currency translation | 106 | 106 | |||||
Unrealized gain (loss) on available-for-sale securities | 39 | 39 | |||||
Net loss | (13,714) | (13,714) | |||||
Ending balance, preferred stock, shares outstanding (in shares) at Mar. 31, 2023 | 0 | ||||||
Ending balance at Mar. 31, 2023 | 358,107 | $ 0 | $ 43 | 619,227 | (534) | (260,629) | |
Ending balance, common stock, shares outstanding (in shares) at Mar. 31, 2023 | 43,289,969 | ||||||
Beginning balance, preferred stock, shares outstanding (in shares) at Dec. 31, 2023 | 0 | 0 | |||||
Beginning balance at Dec. 31, 2023 | $ 337,663 | $ 0 | $ 45 | 652,880 | (345) | (314,917) | |
Beginning balance, common stock, shares outstanding (in shares) at Dec. 31, 2023 | 45,167,225 | 45,167,225 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Stock-based compensation | $ 6,183 | 6,183 | |||||
Stock option exercises (in shares) | 0 | ||||||
Stock issued - on vested RSAs (in shares) | 522,358 | ||||||
Stock issued – on vested RSAs | $ 1 | $ 1 | |||||
Foreign currency translation | (203) | (203) | |||||
Unrealized gain (loss) on available-for-sale securities | (18) | (18) | |||||
Net loss | (10,221) | (10,221) | |||||
Ending balance, preferred stock, shares outstanding (in shares) at Mar. 31, 2024 | 0 | 0 | |||||
Ending balance at Mar. 31, 2024 | $ 333,405 | $ 0 | $ 46 | $ 659,063 | $ (566) | $ (325,138) | |
Ending balance, common stock, shares outstanding (in shares) at Mar. 31, 2024 | 45,689,583 | 45,689,583 |
Unaudited Condensed Consolida_6
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Cash flows from operating activities | ||
Net loss | $ (10,221) | $ (13,714) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation | 1,364 | 1,721 |
Amortization of intangible assets | 914 | 1,459 |
Amortization of loan costs | 0 | 13 |
Stock-based compensation | 6,183 | 7,363 |
Non-cash lease (benefit) expense | (83) | 418 |
Deferred income tax expense | 5 | 13 |
Change in fair value of contingent consideration | 0 | 720 |
Accretion of available-for-sale investments | (182) | (390) |
(Gain) loss on disposal of property and equipment, net | (14) | 68 |
Loss on disposal of assets held for rent, net | 198 | 218 |
Other | 0 | (50) |
Change in operating assets and liabilities, net of effects of acquisitions | ||
Accounts receivable, trade, net | 65 | 3,612 |
Inventories | 42 | (6,425) |
Prepaid expenses and other assets | 2,392 | 661 |
Accounts payable | (1,956) | 157 |
Accrued expenses and other current liabilities | (2,767) | 371 |
Warranty liability | (58) | 583 |
Sales taxes payable | 20 | 510 |
Other | (377) | (20) |
Net cash used in operating activities | (4,475) | (2,712) |
Cash flows from investing activities | ||
Purchases of available-for-sale securities | (6,374) | (8,202) |
Proceeds from sale of available-for-sale securities | 973 | 524 |
Maturities of available-for-sale securities | 6,000 | 14,900 |
Purchases of assets held for rent | (464) | (1,001) |
Purchases of property and equipment | (356) | (3,295) |
Net cash (used in) provided by investing activities | (221) | 2,926 |
Cash flows from financing activities | ||
Payments on equipment loans | (241) | (127) |
Proceeds from exercise of common stock options | 0 | 125 |
Payments on financed insurance premium | (727) | (569) |
Other | 16 | 9 |
Net cash used in financing activities | (952) | (562) |
Net decrease in cash, cash equivalents, and restricted cash | (5,648) | (348) |
Cash, cash equivalents, and restricted cash – beginning of period | 35,438 | 19,473 |
Effects of currency translation on cash, cash equivalents, and restricted cash | (65) | 11 |
Cash, cash equivalents, and restricted cash – end of period | 29,725 | 19,136 |
Non-cash investing and financing activities | ||
Purchase of property and equipment not yet paid | 26 | 347 |
Assets acquired under operating leases | 0 | 880 |
Unrealized gains and losses on currency translation | (6) | 0 |
Unrealized gains and losses on available-for-sale securities | 18 | (39) |
Cash interest paid | $ 445 | $ 497 |
Organization and significant ac
Organization and significant accounting policies | 3 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and significant accounting policies | Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers, and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ to negative 86℃. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our biological and pharmaceutical materials storage services provide facilities that allow for real-time tracking of biologic materials and vaccines that can be stored at a wide range of temperatures. On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). The Global Cooling Divestiture was considered a subsequent event to the financial results presented as of March 31, 2024. Global Cooling is therefore presented as a part of our continuing operations as of the three months ended March 31, 2024. For additional information on the Global Cooling Divestiture, see Note 19: Subsequent events. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2024 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2024 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024 (the “Annual Report”). The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, Global Cooling, Inc. doing business as Stirling Ultracold (“Global Cooling” or “GCI”), and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheets, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Comprehensive Loss, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Significant accounting policies There have been no significant changes to the accounting policies during the three months ended March 31, 2024, as compared to the significant accounting policies described in our Annual Report. Liquidity and capital resources On March 31, 2024 and December 31, 2023, we had $46.1 million and $52.3 million in cash, cash equivalents, and available-for-sale securities, respectively. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q (this “Form 10-Q”). Risks and uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates. For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q. Concentrations of credit risk and business risk Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue March 31, December 31, Three Months Ended 2024 2023 2024 2023 Customer A 12 % 14 % * * Customer B * * 10 % 14 % Customer C * * 11 % 10 % * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s products representing more than 10% of the Company’s total revenue: Three Months Ended Product revenue concentration 2024 2023 CryoStor 41 % 44 % 780XLE Freezer 13 % 14 % The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Revenue by customers ’ geographic locations (1) 2024 2023 United States (2) 80 % 79 % Europe, Middle East, Africa (EMEA) 15 % 18 % Other 5 % 3 % Total revenue 100 % 100 % (1) During the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented. (2) The line item presented above previously bifurcated sales between the United States and Canada. Due to the updated methodology for determining the country of origin for sales, it was noted that Canada no longer was a material location to separately disclose. Canada sales have been included within the "Other" line item in the table above and United States sales have been retained as a single line item to more accurately reflect origin of sales for material regions. In the three months ended March 31, 2024, one supplier accounted for 13% of purchases. In the three months ended March 31, 2023, one supplier accounted for 15% of purchases. As of March 31, 2024, one supplier accounted for 11% of our accounts payable. As of December 31, 2023, one supplier accounted for 12% of our accounts payable. Recent accounting pronouncements In March 2024, the SEC adopted final rules on the enhancement and standardization of climate-related disclosures of public companies. The final rules require disclosure of, among other things, material climate-related risks and their impact; activities to mitigate or adapt to material climate-related risks; governance and oversight of climate-related risks; and material Scope 1 and/or Scope 2 greenhouse gas emissions with an accompanying assurance report required following an initial transition period, at a limited assurance level, and then following an additional transition period, at a reasonable assurance level. In addition, the effects of severe weather events and other natural conditions, subject to certain thresholds, and amounts related to carbon offsets and renewable energy credits or certificates are required to be disclosed in the notes to the audited financial statements in certain circumstances. On April 4, 2024, the SEC voluntarily stayed the implementation of the final rules pending the completion of judicial review of the consolidated challenges to the final rules by the Court of Appeals for the Eighth Circuit. The final rules, as originally issued, would be effective for the Company in various fiscal years, starting with its Annual Report on Form 10-K for fiscal year 2025. Disclosures pursuant to the final rules, as originally issued, would be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of the final rules on its Consolidated Financial Statements and disclosures. |
Correction of immaterial errors
Correction of immaterial errors | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Changes and Error Corrections [Abstract] | |
Correction of immaterial errors | Correction of immaterial errors During the three months ended March 31, 2024, we determined that an error existed in our previously issued consolidated financial statements. Specifically, we identified we had not properly accelerated stock compensation expense related to unvested shares of market-based awards of certain employees upon their termination during the fourth quarter of 2023. The error was evaluated under the U.S. Securities and Exchange Commission's ("SEC's") Staff Accounting Bulletin ("SAB") Topic 1M, "Materiality," and SEC SAB Topic 1N, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in the Current Year Financial Statements" to determine the materiality of prior period misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not material to the previously issued consolidated financial statements. Although the error was not material to any period, we corrected the accompanying historical consolidated financial statements for the year ended December 31, 2023 to reflect the additional stock compensation expense incurred within each period for comparative purposes. The following table represents the adjustments to our Consolidated Balance Sheet as of December 31, 2023 in accordance with ASC 250. The adjustments to our Consolidated Statement of Shareholders’ Equity was limited to the adjustments outlined below. The effect of the adjustments to our Consolidated balance Sheet as of December 31, 2023 was as follows (in thousands): December 31, 2023 (In thousands) As reported Adjustment As corrected Additional paid-in-capital $ 651,305 $ 1,575 $ 652,880 Accumulated deficit (313,342) (1,575) (314,917) |
Fair value measurement
Fair value measurement | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Fair value measurement | Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures , (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. The Company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The fair value of the SciSafe contingent consideration liability was valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.2%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not affect the fair value of the contingent consideration if they increase (decrease) beyond certain amounts. At the acquisition date, the contingent consideration was determined to have a fair value of $3.7 million. Subsequent to the acquisition date, the SciSafe contingent consideration liability was re-measured to fair value with changes recorded in the Change in fair value of contingent consideration in the Unaudited Condensed Consolidated Statements of Operations. During the most recent re-measurement of the contingent consideration liability as of December 31, 2023, the Company determined it appropriate to write-off the remaining balance of the SciSafe contingent consideration liability. The target revenue required for earnout was not met during the year ended December 31, 2023 and had been determined to not be probable to achieve in future years. The change in fair value of contingent consideration of $0.7 million associated with the contingent consideration liability was included within the Change in fair value of contingent consideration in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023. There were no remeasurements to fair value during the three months ended March 31, 2024 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023, based on the three-tier fair value hierarchy: (In thousands) As of March 31, 2024 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 16,260 $ - $ - $ 16,260 Available-for-sale securities: U.S. government securities 5,891 - - 5,891 Corporate debt securities - 7,847 - 7,847 Other debt securities - 2,663 - 2,663 Total $ 22,151 $ 10,510 $ - $ 32,661 As of December 31, 2023 Assets: Cash equivalents: Money market accounts $ 25,034 $ - $ - $ 25,034 Available-for-sale securities: U.S. government securities 5,170 - - 5,170 Corporate debt securities - 9,674 - 9,674 Other debt securities - 1,992 - 1,992 Total $ 30,204 $ 11,666 $ - $ 41,870 There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities that are measured using Level 3 inputs for the three months ended March 31, 2023. There was no contingent consideration liability outstanding as of March 31, 2024. Three Months Ended March 31, (In thousands) 2023 Balance at beginning of period $ 4,456 Change in fair value recognized in net loss 720 Balance at end of period $ 5,176 |
Investments
Investments | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: March 31, 2024 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,897 $ - $ (6) $ 5,891 Corporate debt securities 7,851 1 (5) 7,847 Other debt securities 1,842 - (1) 1,841 Total short-term 15,590 1 (12) 15,579 Available-for-sale securities, long-term Other debt securities 823 - (1) 822 Total marketable securities $ 16,413 $ 1 $ (13) $ 16,401 December 31, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,169 $ 1 $ - $ 5,170 Corporate debt securities 9,673 5 (4) 9,674 Other debt securities 1,443 1 - 1,444 Total short-term 16,285 7 (4) 16,288 Available-for-sale securities, long-term Other debt securities 545 3 - 548 Total marketable securities $ 16,830 $ 10 $ (4) $ 16,836 March 31, 2024 (In thousands) Amortized Estimated Due in one year or less $ 15,590 $ 15,579 Due after one year through five years 823 822 Total $ 16,413 $ 16,401 Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series A-1 and A-2 Preferred Stock in iVexSol, Inc. carried at $4.1 million for the periods ending March 31, 2024 and December 31, 2023, and Series E Preferred Stock in PanTHERA CryoSolutions, Inc. carried at $1.0 million as of March 31, 2024 and December 31, 2023. |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2024 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventories consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Raw materials $ 24,330 $ 26,219 Work in progress 6,737 7,128 Finished goods 12,347 10,109 Total inventories $ 43,414 $ 43,456 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Leases | Leases The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases had original lease terms of three one one four one Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Weighted average discount rate - operating leases 4.3 % 4.3 % Weighted average discount rate - finance leases 8.4 % 8.3 % Weighted average remaining lease term in years - operating leases 6.2 6.4 Weighted average remaining lease term in years - finance leases 3.9 4.1 The components of lease expense for the three months ended March 31, 2024 and 2023 were as follows: Three Months Ended (In thousands) 2024 2023 Operating lease costs $ 804 $ 897 Financing lease costs 59 — Short-term lease costs 442 402 Total operating lease costs 1,305 1,299 Variable lease costs 361 259 Total lease costs $ 1,666 $ 1,558 Maturities of our lease liabilities as of March 31, 2024 are as follows: (In thousands) Operating Financing 2024 (9 months remaining) $ 2,471 $ 349 2025 3,030 424 2026 2,574 389 2027 2,280 387 2028 2,042 134 Thereafter 4,896 - Total lease payments 17,293 1,683 Less: interest (2,069) (245) Total present value of lease liabilities $ 15,224 $ 1,438 |
Leases | Leases The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases had original lease terms of three one one four one Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Weighted average discount rate - operating leases 4.3 % 4.3 % Weighted average discount rate - finance leases 8.4 % 8.3 % Weighted average remaining lease term in years - operating leases 6.2 6.4 Weighted average remaining lease term in years - finance leases 3.9 4.1 The components of lease expense for the three months ended March 31, 2024 and 2023 were as follows: Three Months Ended (In thousands) 2024 2023 Operating lease costs $ 804 $ 897 Financing lease costs 59 — Short-term lease costs 442 402 Total operating lease costs 1,305 1,299 Variable lease costs 361 259 Total lease costs $ 1,666 $ 1,558 Maturities of our lease liabilities as of March 31, 2024 are as follows: (In thousands) Operating Financing 2024 (9 months remaining) $ 2,471 $ 349 2025 3,030 424 2026 2,574 389 2027 2,280 387 2028 2,042 134 Thereafter 4,896 - Total lease payments 17,293 1,683 Less: interest (2,069) (245) Total present value of lease liabilities $ 15,224 $ 1,438 |
Assets held for rent
Assets held for rent | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Assets held for rent | Assets held for rent Assets held for rent consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Shippers placed in service $ 9,709 $ 9,866 Fixed assets held for rent 579 1,468 Accumulated depreciation (6,080) (6,272) Subtotal 4,208 5,062 Shippers and related components in production 2,696 2,651 Total $ 6,904 $ 7,713 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.7 million and $0.8 million in depreciation expense related to assets held for rent during the three months ended March 31, 2024 and 2023, respectively. |
Property and equipment
Property and equipment | 3 Months Ended |
Mar. 31, 2024 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment | Property and equipment Property and equipment consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Property and equipment Leasehold improvements $ 5,927 $ 5,913 Furniture and computer equipment 819 820 Manufacturing and other equipment 20,871 19,893 Construction in-progress 4,112 3,953 Subtotal 31,729 30,579 Less: Accumulated depreciation (10,687) (9,502) Property and equipment, net $ 21,042 $ 21,077 Depreciation expense for property and equipment was $0.7 million and $0.9 million for the three months ended March 31, 2024 and 2023, respectively. |
Goodwill and intangible assets
Goodwill and intangible assets | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and intangible assets | Goodwill and intangible assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350. Intangible assets Intangible assets, net consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands, except weighted average useful life) March 31, 2024 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships $ 9,936 $ (4,353) $ 5,583 10.4 Tradenames 8,134 (2,231) 5,903 11.0 Technology - acquired 18,372 (9,705) 8,667 3.8 Non-compete agreements 750 (668) 82 0.5 Total intangible assets $ 37,192 $ (16,957) $ 20,235 7.1 (In thousands, except weighted average useful life) December 31, 2023 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships $ 9,936 $ (4,217) $ 5,719 10.7 Tradenames 8,134 (2,077) 6,057 11.3 Technology - acquired 18,372 (9,123) 9,249 4.1 Non-compete agreements 750 (626) 124 0.8 Total intangible assets $ 37,192 $ (16,043) $ 21,149 7.3 Amortization expense for definite-lived intangible assets was $0.9 million and $1.5 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company expects to record the following amortization expense for definite-lived intangible assets: (In thousands) Amortization For the Years Ending December 31, 2024 (9 months remaining) $ 2,689 2025 3,468 2026 3,358 2027 2,605 2028 1,500 Thereafter 6,615 Total $ 20,235 |
Accrued expenses and other curr
Accrued expenses and other current liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Accrued expenses and other current liabilities | Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Accrued expenses $ 4,253 $ 6,909 Accrued taxes 667 562 Accrued compensation 3,644 3,800 Deferred revenue, current 299 661 Total accrued expenses and other current liabilities $ 8,863 $ 11,932 |
Warranty reserve liability
Warranty reserve liability | 3 Months Ended |
Mar. 31, 2024 | |
Guarantees and Product Warranties [Abstract] | |
Warranty reserve liability | Warranty reserve liability The Company reserves estimated exposures on known claims, as well as anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Three Months Ended (In thousands) 2024 2023 Balance at beginning of period $ 7,858 $ 8,312 Provision for warranties 767 1,891 Settlements of warranty claims (825) (1,308) Balance at end of period $ 7,800 $ 8,895 |
Commitments and contingencies
Commitments and contingencies | 3 Months Ended |
Mar. 31, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason. Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business. The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company. Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of March 31, 2024 and December 31, 2023. Purchase obligations Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of March 31, 2024, our total short-term obligations were $10.0 million. Non-income related taxes Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2023, the Company determined that a sales tax liability related to the periods of 2019 through 2023 was probable and determined an estimated liability. The estimated liability was approximately $5.0 million and $5.4 million as of March 31, 2024 and December 31, 2023, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period. |
Long-term debt
Long-term debt | 3 Months Ended |
Mar. 31, 2024 | |
Debt Disclosure [Abstract] | |
Long-term debt | Long-term debt Global Cooling Term Notes In May 2021, the Company assumed three term notes in the acquisition of Global Cooling. At the time of acquisition, these notes carried aggregate outstanding principal balances of $4.4 million. These term notes bore interest at a floating rate equal to the 3-month LIBOR rate plus 6.5%. The term notes included financial covenants tied to the performance of Global Cooling. In October 2021, the Company entered into amended and restated term notes for all three term notes (the “Global Cooling Term Notes”) with two lenders. As amended, the principal amount borrowed pursuant to the Global Cooling Amended Term Notes” consisted of an aggregate $4.6 million, with one lender providing two term notes in the principal amount of $1.4 million per note and a separate lender providing one term note in the principal amount of $1.8 million. The maturity dates for the Global Cooling Amended Term Notes are July 17, 2024, September 7, 2024, and December 18, 2027, respectively. All three Global Cooling Amended Term Notes bear interest at a fixed rate of 4.0%, were interest-only with one balloon principal payment at maturity, and could be pre-paid without penalty at any time. The Company fully extinguished the Global Cooling Amended Term Notes with maturity dates of September 7, 2024 and July 17, 2024 on September 20, 2022 and July 17, 2023, respectively. All financial covenants included in the original term notes previously in effect were removed upon amendment and restatement pursuant to the Global Cooling Amended Term Notes. In connection with the Global Cooling Divestiture as of April 17, 2024, the Company fully extinguished the remaining balance of the Global Cooling Amended Term Notes, totaling $2.6 million. For additional information regarding the Global Cooling Divestiture and associated costs incurred by the Company, see Note 19: Subsequent events . Term Loan On September 20, 2022, the Company and certain of its subsidiaries entered into a term loan agreement (the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of March 31, 2024, the implied interest rate of the Term Loan is 6.6% and the implied value of the Term Loan is $20.4 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of March 31, 2024, the Company is in compliance with the covenants set forth in the Loan Agreement. On April 17, 2024, the Company entered into a Consent and Second Amendment to the Term Loan (the “Amendment”) by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and the Company and its subsidiaries. For additional information on the Amendment, see Note 19: Subsequent events . Long-term debt consisted of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) Maturity Date Interest Rate 2024 2023 Global Cooling Amended Term Notes Various 4.0 % $ 2,596 $ 2,596 Term Loan Jun-26 7.0 % 20,000 20,000 Insurance premium financing Jul-24 Various 622 1,348 Freezer equipment loan Dec-25 5.7 % 279 317 Manufacturing equipment loans Oct-25 5.7 % 147 172 Freezer installation loan Various 6.3 % 736 807 Other loans Various Various 1 2 Total debt, excluding unamortized debt issuance costs 24,381 25,242 Less: unamortized debt issuance costs (81) (98) Total debt 24,300 25,144 Less: current portion of debt (8,619) (6,833) Total long-term debt $ 15,681 $ 18,311 As of March 31, 2024, the Term Loan was secured by substantially all assets of BioLife, SAVSU, CBS, SciSafe, Global Cooling, and Sexton, other than intellectual property, and the Global Cooling Term Amended Notes were secured by substantially all assets of Global Cooling, which security interest was effectively subordinated to the security interest established by the Loan Agreement. Equipment loans are secured by the financed equipment. In connection with the Global Cooling Divestiture as of April 17, 2024, the Company entered into the Amendment as described above to remove Global Cooling as a party to the Loan Agreement and to release Bank's security interest in the assets of Global Cooling and the shares of capital stock of Global Cooling arising under the Loan Agreement. As of March 31, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2024 (9 months remaining) $ 5,975 2025 10,511 2026 5,218 2027 2,596 2028 - Thereafter - Total debt $ 24,300 |
Revenue
Revenue | 3 Months Ended |
Mar. 31, 2024 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of March 31, 2024 and December 31, 2023, our deferred revenue balance totaled $0.3 million and $0.7 million, respectively. During the three months ended March 31, 2024 and 2023, the Company recognized approximately $0.4 million and $0.2 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year. The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three months ended March 31, 2024. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its biostorage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under annual rental arrangements. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term. The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one customer. This is primarily driven by the customer’s desire to ensure that sufficient storage capacity is available in a specific geographic location for a set period of time. These agreements may include extension and termination clauses. These Service Contracts do not allow for customers to purchase the underlying assets. The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Applying the practical expedient from ASC Topic 842, consistent with the previous guidance, the Company will continue to recognize operating right-of-use asset embedded lessor arrangements on its Unaudited Condensed Consolidated Balance Sheets in operating right-of-use assets. None of the Embedded Leases identified by the Company qualify as a sales-type or direct finance lease. None of the operating leases for which the Company is the lessor include options for the lessee to purchase the underlying asset at the end of the lease term or residual value guarantees, nor are any such operating leases with related parties. Embedded Leases may contain both lease and non-lease components. We have elected to utilize the practical expedient from ASC Topic 842 to account for lease and non-lease components together as a single combined lease component as the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease. Non-lease components of the Company’s rental arrangements include reimbursements of lessor costs. Total bioproduction tools and services revenue for the three months ended March 31, 2024 and 2023 were composed of the following: Three Months Ended (In thousands, except percentages) 2024 2023 Product revenue Freezer and thaw $ 8,334 $ 12,381 Cell processing 16,186 18,993 Biostorage services 283 219 Service revenue Biostorage services 4,975 3,825 Freezer and thaw 113 646 Rental revenue Biostorage services 1,836 1,639 Total revenue $ 31,727 $ 37,703 The following table includes estimated rental revenue expected to be recognized in the future related to Embedded Leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers. The estimated revenue in the following table does not include contracts with the original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of March 31, 2024. As of March 31, 2024, we did not have rental revenue expected to be recognized. The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: (In thousands) 2024 (9 months remaining) Total Service revenue $ 18 $ 18 |
Stock-based compensation
Stock-based compensation | 3 Months Ended |
Mar. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-based compensation | Stock-based compensation Service-based vesting stock options The following is a summary of service-based vesting stock option activity for the March 31, 2024, and the status of service-based vesting stock options outstanding as of March 31, 2024: Three Months Ended Options Wtd. Avg. Exercise Price Outstanding as of beginning of period 217,250 $ 2.21 Exercised — — Outstanding as of March 31, 2024 217,250 $ 2.21 Stock options exercisable as of March 31, 2024 217,250 $ 2.21 As of March 31, 2024, there was $3.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2024. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three months ended March 31, 2024. There were no service-based vesting options granted during the three months ended March 31, 2024. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of March 31, 2024 is 1.8 years. There were no unrecognized compensation costs for service-based vesting stock options as of March 31, 2024. Restricted stock Service-based vesting restricted stock The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2024, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2024: Three Months Ended Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of period 2,312,898 $ 18.32 Granted 186,272 17.36 Vested (221,829) 24.02 Forfeited (51,340) 17.69 Non-vested as of March 31, 2024 2,226,001 $ 17.66 The aggregate fair value of the service-based vesting awards granted was $3.2 million during the three months ended March 31, 2024. The aggregate fair value of the service-based vesting awards that vested was $3.7 million during the three months ended March 31, 2024. We recognized stock compensation expense related to service-based vesting awards of $4.7 million during the three months ended March 31, 2024. As of March 31, 2024, there was $35.4 million in unrecognized compensation costs related to service-based vesting awards. We expect to recognize those costs over 2.6 years. Performance-based restricted stock On March 8, 2024, the Company granted 109,512 shares of performance-based stock to an executive in the form of restricted stock. The shares granted contain performance conditions based on several Company metrics related to future performance. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025. We recognized stock compensation expense of $0.2 million related to performance-based restricted stock awards for the three months ended March 31, 2024. As of March 31, 2024, there was $1.7 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 1.8 years. Non-cash compensation costs are expensed over the period for which performance was measured. The aggregate fair value of the performance-based awards granted during the three months ended March 31, 2024 was $1.9 million. No performance-based awards vested during the three months ended March 31, 2024. No performance-based restricted stock awards were granted or vested during the three months ended March 31, 2023. Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2024 and the status of market-based restricted stock outstanding as of March 31, 2024: Three Months Ended Shares Wtd. Avg. Grant Outstanding as of beginning of period 509,166 $ 26.50 Granted 299,565 23.20 Vested (300,529) 27.97 Non-vested as of March 31, 2024 508,202 $ 25.70 On February 24, 2022, the Company granted 240,428 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on total shareholder return ("TSR"). The TSR market condition measures the Company’s performance against a peer group. On March 8, 2024, the Company’s Compensation Committee determined the TSR attainment was 125% of the targeted shares and 300,529 shares were granted and immediately vested to the executives of the Company based on our TSR during the period beginning on January 1, 2022 through December 31, 2023 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 63%, 0% dividend yield and a risk-free interest rate of 1.5%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.7 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2023. On January 3, 2023, the Company granted 268,738 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2023 through December 31, 2024 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 78%, 0% dividend yield and a risk-free interest rate of 4.4%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024, excluding $1.6 million of expense recognized in 2023 to reflect accelerations in the vesting period of certain awards. On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2024 through December 31, 2025 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 80%, 0% dividend yield and a risk-free interest rate of 4.6%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.3 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2025. We recognized stock compensation expense of $1.1 million and $1.3 million related to market-based restricted stock awards for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, there was $8.6 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. We expect to recognize those costs over 1.5 years. The aggregate fair value of the market-based awards granted was $6.3 million and $6.5 million during the three months ended March 31, 2024 and 2023, respectively. The aggregate fair value of the market-based awards that vested was $5.1 million and $0.7 million during the three months ended March 31, 2024 and 2023, respectively. Total stock compensation expense Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three months ended March 31, 2024 and 2023, as follows: Three Months Ended (In thousands) 2024 2023 Cost of revenue $ 1,120 $ 1,631 General and administrative costs 3,130 3,293 Sales and marketing costs 1,186 1,256 Research and development costs 747 1,183 Total $ 6,183 $ 7,363 |
Income taxes
Income taxes | 3 Months Ended |
Mar. 31, 2024 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Income taxes The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax expense of $0.1 million for the three months ended March 31, 2024 resulted in an effective income tax rate of negative 1.2%. Included in the $0.1 million was a discrete tax expense of $0.6 million related to a stock compensation shortfall, which was offset by a change in the valuation allowance. The Company’s U.S. projected effective income tax rate without discrete items was negative 1.8%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on US deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not that deferred tax assets are realizable. After reviewing the evidence available, the Company’s management believes there is uncertainty regarding the future realizability of the U.S. net operating loss carryforward and is projecting a full valuation allowance of $54.7 million by year end. If operating results improve and projections indicate future utilization of the tax attributes, all or a portion of the valuation allowance would be released, resulting in a corresponding non-cash income tax benefit. |
Net loss per common share
Net loss per common share | 3 Months Ended |
Mar. 31, 2024 | |
Earnings Per Share [Abstract] | |
Net loss per common share | Net loss per common share The Company considers its unvested restricted shares, which contain non-forfeitable rights to dividends, as participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two-class method. Basic earnings per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. The following table presents computations of basic and diluted earnings per share: Three Months Ended (In thousands, except share and earnings per share data) 2024 2023 Basic earnings (loss) per common share Numerator: Net loss $ (10,221) $ (13,714) Net loss allocated to common shareholders (10,221) (13,714) Denominator: Weighted-average common shares issued and outstanding 45,432,426 43,027,612 Basic and diluted loss per common share $ (0.22) $ (0.32) The following table sets forth the number of weighted-average shares of common stock excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended 2024 2023 Stock options and restricted stock awards 3,766,824 3,153,029 Total 3,766,824 3,153,029 |
Employee benefit plan
Employee benefit plan | 3 Months Ended |
Mar. 31, 2024 | |
Retirement Benefits [Abstract] | |
Employee benefit plan | Employee benefit plan The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.3 million in contributions to this plan for the three months ended for both March 31, 2024 and 2023. |
Subsequent events
Subsequent events | 3 Months Ended |
Mar. 31, 2024 | |
Subsequent Events [Abstract] | |
Subsequent events | Subsequent events Stock Purchase Agreement for Global Cooling Divestiture The Company has evaluated events subsequent to March 31, 2024 through the date of this filing to assess the need for potential recognition or disclosure. On April 17, 2024, the Company entered into the Purchase Agreement by and between the Company and GCI Holdings, which is wholly owned by an consulting contractor of Global Cooling, for the sale of all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings for an aggregate purchase price of $1.00. In addition, at the closing of the GCI Divestiture, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $4.9 million in cash funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling. Following the execution of the Purchase Agreement, the GCI Divestiture was consummated on April 17, 2024. The Company expects to recognize a loss on the GCI Divestiture, calculated as follows: (In thousands) April 17, 2024 Selling price: $1 $ — Cash to Global Cooling funded by Company (4,910) Approximate costs to sell Global Cooling (1) (2,409) Negative selling price (7,319) Global Cooling carrying basis as of December 31, 2023 (2) (963) Estimated net loss on disposal $ (8,282) (1) Represents the costs incurred in connection with the GCI Divestiture, including fees to be paid to the broker, attorneys, and other external parties. (2) The Company is utilizing the carrying basis of Global Cooling as of December 31, 2023 as an estimate for its carrying basis as of the date of divestiture. The carrying basis to calculate the loss on disposal will utilize the carrying basis as of the date of divestiture on April 17, 2024, and may differ from the estimate noted here upon disclosure in the second quarter of 2024. The Company’s estimates are subject to a number of assumptions, and actual results may differ. In connection with the Company’s entry into the Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing approximately 11% of its full-time employees). The Company’s Board of Directors approved the RIF on March 29, 2024, and all affected employees were informed by April 18, 2024, following the execution of the Purchase Agreement. The Company expects to recognize approximately $1.6 million of charges in connection with the RIF, comprised of approximately $1.3 million of stock compensation expense and approximately $0.3 million in cash expenditures, substantially all of which are expected to be related to employee severance costs. The Company expects to recognize most of these expenditures in the second quarter of 2024. The Company’s estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the RIF. In addition, the Company expects to recognize approximately $4.5 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with Global Cooling upon the closing of the GCI Divestiture. The following table summarizes the additional costs incurred by the Company in connection with closing the GCI Divestiture and expected to be recorded during the second quarter of 2024: (In thousands) April 17, 2024 Global Cooling Term Notes payoff (1) $ 2,596 Assumed liabilities from Global Cooling (2) 2,353 RIF compensation expenses (3) 1,595 Global Cooling employee stock based compensation expense (4) 4,106 Total $ 10,650 (1) As a condition to close the GCI Divestiture, the Company repaid the balance of the Global Cooling Amended Term Notes. For additional information on the terms of the Global Cooling Term Notes, see Note 13: Long-term debt . (2) As a condition to close the GCI Divestiture, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling to approximately $1.8 million and $0.6 million, respectively. (3) The Company expects to recognize approximately $1.6 million of charges in connection with the RIF, comprised of approximately $1.3 million of stock compensation expense and approximately $0.3 million in cash expenditures, substantially all of which are expected to be related to employee severance costs. (4) The Company expects to recognize approximately $4.5 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with Global Cooling upon the closing of the GCI Divestiture. In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement, pursuant to which the Company will provide certain transition services to Global Cooling for up to 90 days following the Closing Date. Second Amendment to Loan and Security Agreement with Silicon Valley Bank Additionally, on April 17, 2024, the Company entered into the Amendment by and among Bank and Borrower. Pursuant to the Amendment and subject to the conditions set forth therein, Bank consented to the GCI Divestiture and released its security interests in the assets of Global Cooling and the shares of capital stock of Global Cooling arising under the Loan Agreement. In addition, effective as of the closing of the GCI Divestiture, the Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Amendment additionally contained a financial covenant requiring the Company to limit cash outflows and unsecured indebtedness in connection with the Transaction to $15 million or less. The Amendment also contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Pay vs Performance Disclosure | ||
Net loss | $ (10,221) | $ (13,714) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 shares | |
Trading Arrangements, by Individual | |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Aby J. Matthew [Member] | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | The following table identifies and provides the material terms of the Rule 10b5-1 trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted or terminated by our officers and directors during the three months ended March 31, 2024. Name and Position Plan Adoption / Termination Plan Adoption / Termination Date Expiration Date Number of Shares to be Purchased (Sold) under Plan Aby J. Mathew, EVP & Chief Scientific Officer Adoption March 13, 2024 December 31, 2024 (123,404) |
Name | Aby J. Mathew |
Title | EVP & Chief Scientific Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | March 13, 2024 |
Arrangement Duration | 293 days |
Aggregate Available | (123,404) |
Organization and significant _2
Organization and significant accounting policies (Policies) | 3 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Use of estimates | Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. |
Basis of presentation | Basis of presentation The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2024 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2024 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024 (the “Annual Report”). The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, Global Cooling, Inc. doing business as Stirling Ultracold (“Global Cooling” or “GCI”), and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. |
Foreign currency translation | Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheets, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Comprehensive Loss, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. |
Segment reporting | Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. |
Concentrations of credit risk and business risk | Concentrations of credit risk and business risk |
Recent accounting pronouncements | Recent accounting pronouncements In March 2024, the SEC adopted final rules on the enhancement and standardization of climate-related disclosures of public companies. The final rules require disclosure of, among other things, material climate-related risks and their impact; activities to mitigate or adapt to material climate-related risks; governance and oversight of climate-related risks; and material Scope 1 and/or Scope 2 greenhouse gas emissions with an accompanying assurance report required following an initial transition period, at a limited assurance level, and then following an additional transition period, at a reasonable assurance level. In addition, the effects of severe weather events and other natural conditions, subject to certain thresholds, and amounts related to carbon offsets and renewable energy credits or certificates are required to be disclosed in the notes to the audited financial statements in certain circumstances. On April 4, 2024, the SEC voluntarily stayed the implementation of the final rules pending the completion of judicial review of the consolidated challenges to the final rules by the Court of Appeals for the Eighth Circuit. The final rules, as originally issued, would be effective for the Company in various fiscal years, starting with its Annual Report on Form 10-K for fiscal year 2025. Disclosures pursuant to the final rules, as originally issued, would be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of the final rules on its Consolidated Financial Statements and disclosures. |
Organization and significant _3
Organization and significant accounting policies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Concentrations of Credit Risk and Business Risk | For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue March 31, December 31, Three Months Ended 2024 2023 2024 2023 Customer A 12 % 14 % * * Customer B * * 10 % 14 % Customer C * * 11 % 10 % * less than 10% |
Schedule of Product Revenue Concentration | The following table represents the Company’s products representing more than 10% of the Company’s total revenue: Three Months Ended Product revenue concentration 2024 2023 CryoStor 41 % 44 % 780XLE Freezer 13 % 14 % |
Schedule of Revenue by Geographic Areas | The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Revenue by customers ’ geographic locations (1) 2024 2023 United States (2) 80 % 79 % Europe, Middle East, Africa (EMEA) 15 % 18 % Other 5 % 3 % Total revenue 100 % 100 % (1) During the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented. |
Correction of immaterial erro_2
Correction of immaterial errors (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Changes and Error Corrections [Abstract] | |
Schedule of Effect of Adjustments to Financial Statements | The effect of the adjustments to our Consolidated balance Sheet as of December 31, 2023 was as follows (in thousands): December 31, 2023 (In thousands) As reported Adjustment As corrected Additional paid-in-capital $ 651,305 $ 1,575 $ 652,880 Accumulated deficit (313,342) (1,575) (314,917) |
Fair value measurement (Tables)
Fair value measurement (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis | The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023, based on the three-tier fair value hierarchy: (In thousands) As of March 31, 2024 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 16,260 $ - $ - $ 16,260 Available-for-sale securities: U.S. government securities 5,891 - - 5,891 Corporate debt securities - 7,847 - 7,847 Other debt securities - 2,663 - 2,663 Total $ 22,151 $ 10,510 $ - $ 32,661 As of December 31, 2023 Assets: Cash equivalents: Money market accounts $ 25,034 $ - $ - $ 25,034 Available-for-sale securities: U.S. government securities 5,170 - - 5,170 Corporate debt securities - 9,674 - 9,674 Other debt securities - 1,992 - 1,992 Total $ 30,204 $ 11,666 $ - $ 41,870 |
Schedule of the Changes in Fair Value of Contingent Consideration Liabilities | The following table presents the changes in fair value of contingent consideration liabilities that are measured using Level 3 inputs for the three months ended March 31, 2023. There was no contingent consideration liability outstanding as of March 31, 2024. Three Months Ended March 31, (In thousands) 2023 Balance at beginning of period $ 4,456 Change in fair value recognized in net loss 720 Balance at end of period $ 5,176 |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Available-for-Sale Marketable Securities | The Company’s portfolio of available-for-sale marketable securities consists of the following: March 31, 2024 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,897 $ - $ (6) $ 5,891 Corporate debt securities 7,851 1 (5) 7,847 Other debt securities 1,842 - (1) 1,841 Total short-term 15,590 1 (12) 15,579 Available-for-sale securities, long-term Other debt securities 823 - (1) 822 Total marketable securities $ 16,413 $ 1 $ (13) $ 16,401 December 31, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,169 $ 1 $ - $ 5,170 Corporate debt securities 9,673 5 (4) 9,674 Other debt securities 1,443 1 - 1,444 Total short-term 16,285 7 (4) 16,288 Available-for-sale securities, long-term Other debt securities 545 3 - 548 Total marketable securities $ 16,830 $ 10 $ (4) $ 16,836 March 31, 2024 (In thousands) Amortized Estimated Due in one year or less $ 15,590 $ 15,579 Due after one year through five years 823 822 Total $ 16,413 $ 16,401 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventories consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Raw materials $ 24,330 $ 26,219 Work in progress 6,737 7,128 Finished goods 12,347 10,109 Total inventories $ 43,414 $ 43,456 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Schedule of Operating and Finance Lease Terms and Discount Rates | The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Weighted average discount rate - operating leases 4.3 % 4.3 % Weighted average discount rate - finance leases 8.4 % 8.3 % Weighted average remaining lease term in years - operating leases 6.2 6.4 Weighted average remaining lease term in years - finance leases 3.9 4.1 |
Schedule of Lease Expense | The components of lease expense for the three months ended March 31, 2024 and 2023 were as follows: Three Months Ended (In thousands) 2024 2023 Operating lease costs $ 804 $ 897 Financing lease costs 59 — Short-term lease costs 442 402 Total operating lease costs 1,305 1,299 Variable lease costs 361 259 Total lease costs $ 1,666 $ 1,558 |
Schedule of Maturities of Operating Lease Liabilities | Maturities of our lease liabilities as of March 31, 2024 are as follows: (In thousands) Operating Financing 2024 (9 months remaining) $ 2,471 $ 349 2025 3,030 424 2026 2,574 389 2027 2,280 387 2028 2,042 134 Thereafter 4,896 - Total lease payments 17,293 1,683 Less: interest (2,069) (245) Total present value of lease liabilities $ 15,224 $ 1,438 |
Schedule of Maturities of Finance Lease Liabilities | Maturities of our lease liabilities as of March 31, 2024 are as follows: (In thousands) Operating Financing 2024 (9 months remaining) $ 2,471 $ 349 2025 3,030 424 2026 2,574 389 2027 2,280 387 2028 2,042 134 Thereafter 4,896 - Total lease payments 17,293 1,683 Less: interest (2,069) (245) Total present value of lease liabilities $ 15,224 $ 1,438 |
Assets held for rent (Tables)
Assets held for rent (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Assets Held For Rent | Assets held for rent consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Shippers placed in service $ 9,709 $ 9,866 Fixed assets held for rent 579 1,468 Accumulated depreciation (6,080) (6,272) Subtotal 4,208 5,062 Shippers and related components in production 2,696 2,651 Total $ 6,904 $ 7,713 |
Property and equipment (Tables)
Property and equipment (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Property and equipment consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Property and equipment Leasehold improvements $ 5,927 $ 5,913 Furniture and computer equipment 819 820 Manufacturing and other equipment 20,871 19,893 Construction in-progress 4,112 3,953 Subtotal 31,729 30,579 Less: Accumulated depreciation (10,687) (9,502) Property and equipment, net $ 21,042 $ 21,077 |
Goodwill and intangible assets
Goodwill and intangible assets (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Finite-Lived Intangible Assets | Intangible assets, net consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands, except weighted average useful life) March 31, 2024 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships $ 9,936 $ (4,353) $ 5,583 10.4 Tradenames 8,134 (2,231) 5,903 11.0 Technology - acquired 18,372 (9,705) 8,667 3.8 Non-compete agreements 750 (668) 82 0.5 Total intangible assets $ 37,192 $ (16,957) $ 20,235 7.1 (In thousands, except weighted average useful life) December 31, 2023 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships $ 9,936 $ (4,217) $ 5,719 10.7 Tradenames 8,134 (2,077) 6,057 11.3 Technology - acquired 18,372 (9,123) 9,249 4.1 Non-compete agreements 750 (626) 124 0.8 Total intangible assets $ 37,192 $ (16,043) $ 21,149 7.3 |
Schedule of Amortization Expense for Finite-Lived Intangible Assets | As of March 31, 2024, the Company expects to record the following amortization expense for definite-lived intangible assets: (In thousands) Amortization For the Years Ending December 31, 2024 (9 months remaining) $ 2,689 2025 3,468 2026 3,358 2027 2,605 2028 1,500 Thereafter 6,615 Total $ 20,235 |
Accrued expenses and other cu_2
Accrued expenses and other current liabilities (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consist of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) 2024 2023 Accrued expenses $ 4,253 $ 6,909 Accrued taxes 667 562 Accrued compensation 3,644 3,800 Deferred revenue, current 299 661 Total accrued expenses and other current liabilities $ 8,863 $ 11,932 |
Warranty reserve liability (Tab
Warranty reserve liability (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Guarantees and Product Warranties [Abstract] | |
Schedule of Product Warranty Liability | A rollforward of our warranty liability is as follows: Three Months Ended (In thousands) 2024 2023 Balance at beginning of period $ 7,858 $ 8,312 Provision for warranties 767 1,891 Settlements of warranty claims (825) (1,308) Balance at end of period $ 7,800 $ 8,895 |
Long-term debt (Tables)
Long-term debt (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | Long-term debt consisted of the following as of March 31, 2024 and December 31, 2023: March 31, December 31, (In thousands) Maturity Date Interest Rate 2024 2023 Global Cooling Amended Term Notes Various 4.0 % $ 2,596 $ 2,596 Term Loan Jun-26 7.0 % 20,000 20,000 Insurance premium financing Jul-24 Various 622 1,348 Freezer equipment loan Dec-25 5.7 % 279 317 Manufacturing equipment loans Oct-25 5.7 % 147 172 Freezer installation loan Various 6.3 % 736 807 Other loans Various Various 1 2 Total debt, excluding unamortized debt issuance costs 24,381 25,242 Less: unamortized debt issuance costs (81) (98) Total debt 24,300 25,144 Less: current portion of debt (8,619) (6,833) Total long-term debt $ 15,681 $ 18,311 |
Schedule of Maturities of Long-Term Debt | As of March 31, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2024 (9 months remaining) $ 5,975 2025 10,511 2026 5,218 2027 2,596 2028 - Thereafter - Total debt $ 24,300 |
Revenue (Tables)
Revenue (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Bioproduction Tools and Service Revenues | Total bioproduction tools and services revenue for the three months ended March 31, 2024 and 2023 were composed of the following: Three Months Ended (In thousands, except percentages) 2024 2023 Product revenue Freezer and thaw $ 8,334 $ 12,381 Cell processing 16,186 18,993 Biostorage services 283 219 Service revenue Biostorage services 4,975 3,825 Freezer and thaw 113 646 Rental revenue Biostorage services 1,836 1,639 Total revenue $ 31,727 $ 37,703 |
Schedule of Remaining Performance Obligations | The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: (In thousands) 2024 (9 months remaining) Total Service revenue $ 18 $ 18 |
Stock-based compensation (Table
Stock-based compensation (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Service Vesting-Based Stock Option Activity | The following is a summary of service-based vesting stock option activity for the March 31, 2024, and the status of service-based vesting stock options outstanding as of March 31, 2024: Three Months Ended Options Wtd. Avg. Exercise Price Outstanding as of beginning of period 217,250 $ 2.21 Exercised — — Outstanding as of March 31, 2024 217,250 $ 2.21 Stock options exercisable as of March 31, 2024 217,250 $ 2.21 |
Schedule of Service Vesting-Based and Market Based Restricted Stock Activity | The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2024, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2024: Three Months Ended Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of period 2,312,898 $ 18.32 Granted 186,272 17.36 Vested (221,829) 24.02 Forfeited (51,340) 17.69 Non-vested as of March 31, 2024 2,226,001 $ 17.66 The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2024 and the status of market-based restricted stock outstanding as of March 31, 2024: Three Months Ended Shares Wtd. Avg. Grant Outstanding as of beginning of period 509,166 $ 26.50 Granted 299,565 23.20 Vested (300,529) 27.97 Non-vested as of March 31, 2024 508,202 $ 25.70 |
Schedule of Stock Compensation Expense | We recorded total stock compensation expense for the three months ended March 31, 2024 and 2023, as follows: Three Months Ended (In thousands) 2024 2023 Cost of revenue $ 1,120 $ 1,631 General and administrative costs 3,130 3,293 Sales and marketing costs 1,186 1,256 Research and development costs 747 1,183 Total $ 6,183 $ 7,363 |
Net loss per common share (Tabl
Net loss per common share (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted, Two Class Method | The following table presents computations of basic and diluted earnings per share: Three Months Ended (In thousands, except share and earnings per share data) 2024 2023 Basic earnings (loss) per common share Numerator: Net loss $ (10,221) $ (13,714) Net loss allocated to common shareholders (10,221) (13,714) Denominator: Weighted-average common shares issued and outstanding 45,432,426 43,027,612 Basic and diluted loss per common share $ (0.22) $ (0.32) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table sets forth the number of weighted-average shares of common stock excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended 2024 2023 Stock options and restricted stock awards 3,766,824 3,153,029 Total 3,766,824 3,153,029 |
Subsequent events (Tables)
Subsequent events (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Subsequent Events [Abstract] | |
Disposal Groups, Including Discontinued Operations | The Company expects to recognize a loss on the GCI Divestiture, calculated as follows: (In thousands) April 17, 2024 Selling price: $1 $ — Cash to Global Cooling funded by Company (4,910) Approximate costs to sell Global Cooling (1) (2,409) Negative selling price (7,319) Global Cooling carrying basis as of December 31, 2023 (2) (963) Estimated net loss on disposal $ (8,282) (1) Represents the costs incurred in connection with the GCI Divestiture, including fees to be paid to the broker, attorneys, and other external parties. (2) The Company is utilizing the carrying basis of Global Cooling as of December 31, 2023 as an estimate for its carrying basis as of the date of divestiture. The carrying basis to calculate the loss on disposal will utilize the carrying basis as of the date of divestiture on April 17, 2024, and may differ from the estimate noted here upon disclosure in the second quarter of 2024. The following table summarizes the additional costs incurred by the Company in connection with closing the GCI Divestiture and expected to be recorded during the second quarter of 2024: (In thousands) April 17, 2024 Global Cooling Term Notes payoff (1) $ 2,596 Assumed liabilities from Global Cooling (2) 2,353 RIF compensation expenses (3) 1,595 Global Cooling employee stock based compensation expense (4) 4,106 Total $ 10,650 (1) As a condition to close the GCI Divestiture, the Company repaid the balance of the Global Cooling Amended Term Notes. For additional information on the terms of the Global Cooling Term Notes, see Note 13: Long-term debt . (2) As a condition to close the GCI Divestiture, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling to approximately $1.8 million and $0.6 million, respectively. (3) The Company expects to recognize approximately $1.6 million of charges in connection with the RIF, comprised of approximately $1.3 million of stock compensation expense and approximately $0.3 million in cash expenditures, substantially all of which are expected to be related to employee severance costs. (4) The Company expects to recognize approximately $4.5 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with Global Cooling upon the closing of the GCI Divestiture. |
Organization and significant _4
Organization and significant accounting policies - Narrative (Details) $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 USD ($) reportable_segment reporting_unit | Mar. 31, 2023 | Dec. 31, 2023 USD ($) | |
Short-Term Debt [Line Items] | |||
Number of reportable segments | reportable_segment | 1 | ||
Number of reporting units | reporting_unit | 1 | ||
Cash, cash equivalents, and available-for-sale securities | $ | $ 46.1 | $ 52.3 | |
Supply Purchase | Supplier Concentration Risk | One Supplier | |||
Short-Term Debt [Line Items] | |||
Concentration risk, percent | 13% | 15% | |
Accounts Payable | Supplier Concentration Risk | One Supplier | |||
Short-Term Debt [Line Items] | |||
Concentration risk, percent | 11% | 12% |
Organization and significant _5
Organization and significant accounting policies - Schedule of Concentrations of Credit Risk and Business Risk (Details) - Customer Concentration Risk | 3 Months Ended | ||
Mar. 31, 2024 | Dec. 31, 2023 | Mar. 31, 2023 | |
Accounts Receivable | Customer A | |||
Concentration Risk [Line Items] | |||
Concentration risk, percent | 12% | 14% | |
Revenue | Customer B | |||
Concentration Risk [Line Items] | |||
Concentration risk, percent | 10% | 14% | |
Revenue | Customer C | |||
Concentration Risk [Line Items] | |||
Concentration risk, percent | 11% | 10% |
Organization and significant _6
Organization and significant accounting policies - Schedule of Product Revenue Concentration (Details) - Revenue | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Product revenue concentration | CryoStor | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 41% | 44% |
Product revenue concentration | 780XLE Freezer | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 13% | 14% |
Revenue by customers' geographic locations | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 100% | 100% |
Revenue by customers' geographic locations | United States | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 80% | 79% |
Revenue by customers' geographic locations | Europe, Middle East, Africa (EMEA) | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 15% | 18% |
Revenue by customers' geographic locations | Other | ||
Concentration Risk [Line Items] | ||
Concentration risk, percent | 5% | 3% |
Correction of immaterial erro_3
Correction of immaterial errors - Schedule of Effect of Adjustments to Financial Statements (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Unaudited Condensed Consolidated Balance Sheet | ||
Additional paid-in-capital | $ 652,880 | |
Accumulated deficit | $ (325,138) | (314,917) |
As reported | ||
Unaudited Condensed Consolidated Balance Sheet | ||
Additional paid-in-capital | 651,305 | |
Accumulated deficit | (313,342) | |
Adjustment | ||
Unaudited Condensed Consolidated Balance Sheet | ||
Additional paid-in-capital | 1,575 | |
Accumulated deficit | $ (1,575) |
Fair value measurement - Narrat
Fair value measurement - Narrative (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Oct. 01, 2020 USD ($) | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Change in fair value of contingent consideration, increase (decrease) | $ 0 | $ 720 | |
SciSafe Holdings, Inc | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration, liability | $ 3,700 | ||
Change in fair value of contingent consideration, increase (decrease) | $ 700 | ||
SciSafe Holdings, Inc | Discount Rate | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration, liability, measurement input | 0.045 | ||
SciSafe Holdings, Inc | Risk Free Interest Rate | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration, liability, measurement input | 0.002 | ||
SciSafe Holdings, Inc | Asset Price Volatility | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration, liability, measurement input | 0.60 | ||
SciSafe Holdings, Inc | Revenue Volatility | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration, liability, measurement input | 0.15 |
Fair value measurement - Schedu
Fair value measurement - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Assets: | ||
Available-for-sale securities | $ 16,401 | $ 16,836 |
Fair Value, Recurring | ||
Assets: | ||
Assets | 32,661 | 41,870 |
Fair Value, Recurring | U.S. government securities | ||
Assets: | ||
Available-for-sale securities | 5,891 | 5,170 |
Fair Value, Recurring | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 7,847 | 9,674 |
Fair Value, Recurring | Other debt securities | ||
Assets: | ||
Available-for-sale securities | 2,663 | 1,992 |
Fair Value, Recurring | Money market accounts | ||
Assets: | ||
Cash equivalents | 16,260 | 25,034 |
Fair Value, Recurring | Level 1 | ||
Assets: | ||
Assets | 22,151 | 30,204 |
Fair Value, Recurring | Level 1 | U.S. government securities | ||
Assets: | ||
Available-for-sale securities | 5,891 | 5,170 |
Fair Value, Recurring | Level 1 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 1 | Other debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 1 | Money market accounts | ||
Assets: | ||
Cash equivalents | 16,260 | 25,034 |
Fair Value, Recurring | Level 2 | ||
Assets: | ||
Assets | 10,510 | 11,666 |
Fair Value, Recurring | Level 2 | U.S. government securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 2 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 7,847 | 9,674 |
Fair Value, Recurring | Level 2 | Other debt securities | ||
Assets: | ||
Available-for-sale securities | 2,663 | 1,992 |
Fair Value, Recurring | Level 2 | Money market accounts | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Fair Value, Recurring | Level 3 | ||
Assets: | ||
Assets | 0 | 0 |
Fair Value, Recurring | Level 3 | U.S. government securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 3 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 3 | Other debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Recurring | Level 3 | Money market accounts | ||
Assets: | ||
Cash equivalents | $ 0 | $ 0 |
Fair value measurement - Sche_2
Fair value measurement - Schedule of the Changes in Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities $ in Thousands | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Beginning balance | $ 4,456 |
Change in fair value recognized in net loss | 720 |
Ending balance | $ 5,176 |
Investments - Schedule of Avail
Investments - Schedule of Available-for-Sale Marketable Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Debt Securities, Available-for-Sale [Line Items] | ||
Amortized Cost, current portion | $ 15,590 | $ 16,285 |
Gross unrealized Gains, current portion | 1 | 7 |
Gross unrealized Losses, current portion | (12) | (4) |
Available-for-sale securities, current portion | 15,579 | 16,288 |
Amortized Cost, long term | 823 | |
Available-for-sale securities, long-term | 822 | 548 |
Total | 16,413 | 16,830 |
Total marketable securities, Gross Unrealized Gains | 1 | 10 |
Total marketable securities, Gross Unrealized Losses | (13) | (4) |
Estimated Fair Value, Total marketable securities | 16,401 | 16,836 |
Amortized Cost | ||
Due in one year or less | 15,590 | 16,285 |
Due after one year through five years | 823 | |
Total | 16,413 | 16,830 |
Estimated Fair Value | ||
Due in one year or less | 15,579 | 16,288 |
Due after one year through five years | 822 | |
Total | 16,401 | 16,836 |
U.S. government securities | ||
Debt Securities, Available-for-Sale [Line Items] | ||
Amortized Cost, current portion | 5,897 | 5,169 |
Gross unrealized Gains, current portion | 0 | 1 |
Gross unrealized Losses, current portion | (6) | 0 |
Available-for-sale securities, current portion | 5,891 | 5,170 |
Amortized Cost | ||
Due in one year or less | 5,897 | 5,169 |
Estimated Fair Value | ||
Due in one year or less | 5,891 | 5,170 |
Corporate debt securities | ||
Debt Securities, Available-for-Sale [Line Items] | ||
Amortized Cost, current portion | 7,851 | 9,673 |
Gross unrealized Gains, current portion | 1 | 5 |
Gross unrealized Losses, current portion | (5) | (4) |
Available-for-sale securities, current portion | 7,847 | 9,674 |
Amortized Cost | ||
Due in one year or less | 7,851 | 9,673 |
Estimated Fair Value | ||
Due in one year or less | 7,847 | 9,674 |
Other debt securities | ||
Debt Securities, Available-for-Sale [Line Items] | ||
Amortized Cost, current portion | 1,842 | 1,443 |
Gross unrealized Gains, current portion | 0 | 1 |
Gross unrealized Losses, current portion | (1) | 0 |
Available-for-sale securities, current portion | 1,841 | 1,444 |
Amortized Cost, long term | 823 | 545 |
Gross unrealized Gains, long term | 0 | 3 |
Gross unrealized losses, long term | (1) | 0 |
Available-for-sale securities, long-term | 822 | 548 |
Amortized Cost | ||
Due in one year or less | 1,842 | 1,443 |
Due after one year through five years | 823 | 545 |
Estimated Fair Value | ||
Due in one year or less | $ 1,841 | $ 1,444 |
Investments - Narrative (Detail
Investments - Narrative (Details) - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
Series A-1 and A-2, Preferred Stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Fair value of non-marketable equity securities without readily determinable fair value | $ 4.1 | $ 4.1 |
Series E Preferred Stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Fair value of non-marketable equity securities without readily determinable fair value | $ 1 | $ 1 |
Inventories - Schedule of Inven
Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 24,330 | $ 26,219 |
Work in progress | 6,737 | 7,128 |
Finished goods | 12,347 | 10,109 |
Total inventories | $ 43,414 | $ 43,456 |
Leases - Narrative (Details)
Leases - Narrative (Details) | Mar. 31, 2024 |
Real Estate Lease | Minimum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 3 years |
Operating lease, remaining lease term | 1 year |
Operating lease, renewal term | 1 year |
Real Estate Lease | Maximum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 11 years |
Operating lease, remaining lease term | 8 years |
Operating lease, renewal term | 5 years |
Vehicle and Other Equipment | Minimum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 4 years |
Operating lease, remaining lease term | 1 year |
Vehicle and Other Equipment | Maximum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term of contract | 5 years |
Operating lease, remaining lease term | 5 years |
Leases - Schedule of Operating
Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details) | Mar. 31, 2024 | Dec. 31, 2023 |
Leases [Abstract] | ||
Weighted average discount rate - operating leases | 4.30% | 4.30% |
Weighted average discount rate - finance leases | 8.40% | 8.30% |
Weighted average remaining lease term in years - operating leases | 6 years 2 months 12 days | 6 years 4 months 24 days |
Weighted average remaining lease term in years - finance leases | 3 years 10 months 24 days | 4 years 1 month 6 days |
Leases - Schedule of Lease Expe
Leases - Schedule of Lease Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Leases [Abstract] | ||
Operating lease costs | $ 804 | $ 897 |
Financing lease costs | 59 | 0 |
Short-term lease costs | 442 | 402 |
Total operating lease costs | 1,305 | 1,299 |
Variable lease costs | 361 | 259 |
Total lease costs | $ 1,666 | $ 1,558 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
Operating Leases | |
2024 (9 months remaining) | $ 2,471 |
2025 | 3,030 |
2026 | 2,574 |
2027 | 2,280 |
2028 | 2,042 |
Thereafter | 4,896 |
Total lease payments | 17,293 |
Less: interest | (2,069) |
Total present value of lease liabilities | 15,224 |
Financing Leases | |
2024 (9 months remaining) | 349 |
2025 | 424 |
2026 | 389 |
2027 | 387 |
2028 | 134 |
Thereafter | 0 |
Total lease payments | 1,683 |
Less: interest | (245) |
Total present value of lease liabilities | $ 1,438 |
Assets held for rent - Schedule
Assets held for rent - Schedule of Assets Held for Rent (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Shippers placed in service | $ 9,709 | $ 9,866 |
Fixed assets held for rent | 579 | 1,468 |
Accumulated depreciation | (6,080) | (6,272) |
Subtotal | 4,208 | 5,062 |
Shippers and related components in production | 2,696 | 2,651 |
Total | $ 6,904 | $ 7,713 |
Assets held for rent - Narrativ
Assets held for rent - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Assets held for rent, depreciation expense | $ 0.7 | $ 0.8 |
Property and equipment - Schedu
Property and equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Property, Plant and Equipment [Line Items] | ||
Subtotal | $ 31,729 | $ 30,579 |
Less: Accumulated depreciation | (10,687) | (9,502) |
Property and equipment, net | 21,042 | 21,077 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Subtotal | 5,927 | 5,913 |
Furniture and computer equipment | ||
Property, Plant and Equipment [Line Items] | ||
Subtotal | 819 | 820 |
Manufacturing and other equipment | ||
Property, Plant and Equipment [Line Items] | ||
Subtotal | 20,871 | 19,893 |
Construction in-progress | ||
Property, Plant and Equipment [Line Items] | ||
Subtotal | $ 4,112 | $ 3,953 |
Property and equipment - Narrat
Property and equipment - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | ||
Property and equipment, depreciation expense | $ 0.7 | $ 0.9 |
Goodwill and intangible asset_2
Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Finite-Lived Intangible Assets [Line Items] | ||
Accumulated Amortization | $ (16,957) | $ (16,043) |
Total | $ 20,235 | |
Weighted Average Useful Life (in years) | 7 years 1 month 6 days | 7 years 3 months 18 days |
Intangible assets, gross | $ 37,192 | $ 37,192 |
Intangible assets, net | 20,235 | 21,149 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 9,936 | 9,936 |
Accumulated Amortization | (4,353) | (4,217) |
Total | $ 5,583 | $ 5,719 |
Weighted Average Useful Life (in years) | 10 years 4 months 24 days | 10 years 8 months 12 days |
Tradenames | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 8,134 | $ 8,134 |
Accumulated Amortization | (2,231) | (2,077) |
Total | $ 5,903 | $ 6,057 |
Weighted Average Useful Life (in years) | 11 years | 11 years 3 months 18 days |
Technology - acquired | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 18,372 | $ 18,372 |
Accumulated Amortization | (9,705) | (9,123) |
Total | $ 8,667 | $ 9,249 |
Weighted Average Useful Life (in years) | 3 years 9 months 18 days | 4 years 1 month 6 days |
Non-compete agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 750 | $ 750 |
Accumulated Amortization | (668) | (626) |
Total | $ 82 | $ 124 |
Weighted Average Useful Life (in years) | 6 months | 9 months 18 days |
Goodwill and intangible asset_3
Goodwill and intangible assets - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Intangible asset amortization | $ 914 | $ 1,459 |
Goodwill and intangible asset_4
Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2024 (9 months remaining) | $ 2,689 |
2025 | 3,468 |
2026 | 3,358 |
2027 | 2,605 |
2028 | 1,500 |
Thereafter | 6,615 |
Total | $ 20,235 |
Accrued expenses and other cu_3
Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Investments, Debt and Equity Securities [Abstract] | ||
Accrued expenses | $ 4,253 | $ 6,909 |
Accrued taxes | 667 | 562 |
Accrued compensation | 3,644 | 3,800 |
Deferred revenue, current | 299 | 661 |
Total accrued expenses and other current liabilities | $ 8,863 | $ 11,932 |
Warranty reserve liability - Sc
Warranty reserve liability - Schedule of Product Warranty Liability (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] | ||
Balance at beginning of period | $ 7,858 | $ 8,312 |
Provision for warranties | 767 | 1,891 |
Settlements of warranty claims | (825) | (1,308) |
Balance at end of period | $ 7,800 | $ 8,895 |
Commitments and contingencies (
Commitments and contingencies (Details) - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
Commitments and Contingencies Disclosure [Abstract] | ||
Short-term purchase obligations | $ 10 | |
Sales and excise tax payable | $ 5 | $ 5.4 |
Long-term debt - Narrative (Det
Long-term debt - Narrative (Details) $ in Thousands | 1 Months Ended | |||||
Apr. 17, 2024 USD ($) | Sep. 20, 2022 USD ($) | May 31, 2021 USD ($) note | Mar. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Oct. 31, 2021 USD ($) | |
Debt Instrument [Line Items] | ||||||
Number of term notes assumed | note | 3 | |||||
Total debt, excluding unamortized debt issuance costs | $ 24,381 | $ 25,242 | ||||
The 2023 Term Loan | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | $ 20,400 | |||||
Debt instrument, maximum borrowing capacity | $ 60,000 | |||||
Maximum borrowing capacity | 30,000 | |||||
Options to borrow | 10,000 | |||||
Debt instrument, additional maximum amount upon certain milestone achievements | 10,000 | |||||
Debt instrument, additional maximum at discretion of lender | 10,000 | |||||
Proceeds from term loans | $ 20,000 | |||||
Debt instrument, interest rate, maximum stated percentage for each tranche borrowed | 1% | |||||
Debt instrument, balloon payment due | $ 1,200 | |||||
Interest rate | 6.60% | |||||
Prime Rate | The 2023 Term Loan | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, basis spread on variable rate | 0.50% | |||||
Notes Payable | ||||||
Debt Instrument [Line Items] | ||||||
Total debt, excluding unamortized debt issuance costs | $ 4,400 | |||||
Debt instrument, face amount | $ 4,600 | |||||
Notes Payable | Subsequent Event | ||||||
Debt Instrument [Line Items] | ||||||
Extinguishment of debt, amount | $ 2,600 | |||||
Notes Payable | Advantage Term Note 1 | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | 1,400 | |||||
Notes Payable | Enhanced Term Note | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | $ 1,800 | |||||
Interest rate | 4% | |||||
Notes Payable | London Interbank Offered Rate (LIBOR) 1 | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, basis spread on variable rate | 6.50% |
Long-term debt - Schedule of De
Long-term debt - Schedule of Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Debt Instrument [Line Items] | ||
Total debt, excluding unamortized debt issuance costs | $ 24,381 | $ 25,242 |
Less: unamortized debt issuance costs | (81) | (98) |
Total debt | 24,300 | 25,144 |
Less: current portion of debt | (8,619) | (6,833) |
Total long-term debt | $ 15,681 | $ 18,311 |
Global Cooling Amended Term Notes | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4% | 4% |
Total debt, excluding unamortized debt issuance costs | $ 2,596 | $ 2,596 |
Term Loan | ||
Debt Instrument [Line Items] | ||
Interest Rate | 7% | 7% |
Total debt, excluding unamortized debt issuance costs | $ 20,000 | $ 20,000 |
Insurance premium financing | ||
Debt Instrument [Line Items] | ||
Total debt, excluding unamortized debt issuance costs | $ 622 | $ 1,348 |
Freezer equipment loan | ||
Debt Instrument [Line Items] | ||
Interest Rate | 5.70% | 5.70% |
Total debt, excluding unamortized debt issuance costs | $ 279 | $ 317 |
Manufacturing equipment loans | ||
Debt Instrument [Line Items] | ||
Interest Rate | 5.70% | 5.70% |
Total debt, excluding unamortized debt issuance costs | $ 147 | $ 172 |
Freezer installation loan | ||
Debt Instrument [Line Items] | ||
Interest Rate | 6.30% | 6.30% |
Total debt, excluding unamortized debt issuance costs | $ 736 | $ 807 |
Other loans | ||
Debt Instrument [Line Items] | ||
Total debt, excluding unamortized debt issuance costs | 1 | 2 |
Total long-term debt | ||
Debt Instrument [Line Items] | ||
Total long-term debt | $ 15,681 | $ 18,311 |
Long-term debt - Schedule of Ma
Long-term debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Debt Disclosure [Abstract] | ||
2024 (9 months remaining) | $ 5,975 | |
2025 | 10,511 | |
2026 | 5,218 | |
2027 | 2,596 | |
2028 | 0 | |
Thereafter | 0 | |
Total debt | $ 24,300 | $ 25,144 |
Revenue - Narrative (Details)
Revenue - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |||
Deferred revenue | $ 0.3 | $ 0.7 | |
Deferred revenue, revenue recognized | $ 0.4 | $ 0.2 |
Revenue - Schedule of Bioproduc
Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | $ 31,727 | $ 37,703 |
Product revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 24,803 | 31,593 |
Freezer and thaw | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 8,334 | 12,381 |
Cell processing | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 16,186 | 18,993 |
Biostorage services | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 283 | 219 |
Service revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 5,088 | 4,471 |
Biostorage services | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 4,975 | 3,825 |
Freezer and thaw | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 113 | 646 |
Rental revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | 1,836 | 1,639 |
Biostorage services | ||
Disaggregation of Revenue [Line Items] | ||
Total product, rental, and service revenue | $ 1,836 | $ 1,639 |
Revenue - Schedule of Remaining
Revenue - Schedule of Remaining Performance Obligations (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
Service revenue | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 18 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | Rental revenue | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 9 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01 | Service revenue | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, amount | $ 18 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 9 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Rental revenue | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Service revenue | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Stock-based compensation - Sche
Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
Options | |
Outstanding as of beginning of period (in shares) | shares | 217,250 |
Exercised (in shares) | shares | 0 |
Outstanding as of end of period (in shares) | shares | 217,250 |
Stock options exercisable at end of period (in shares) | shares | 217,250 |
Wtd. Avg. Exercise Price | |
Outstanding as of beginning of period (in dollars per share) | $ / shares | $ 2.21 |
Exercised (in dollars per share) | $ / shares | 0 |
Outstanding as of end of period (in dollars per share) | $ / shares | 2.21 |
Stock options exercisable at end of period (in dollars per share) | $ / shares | $ 2.21 |
Stock-based compensation - Narr
Stock-based compensation - Narrative (Details) | 3 Months Ended | 12 Months Ended | ||||
Mar. 08, 2024 USD ($) peer $ / shares shares | Jan. 03, 2023 USD ($) peer shares | Feb. 24, 2022 USD ($) peer shares | Mar. 31, 2024 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) shares | Dec. 31, 2023 USD ($) $ / shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Aggregate intrinsic value of exercisable service vesting-based stock options | $ 3,600,000 | |||||
Share-based payment arrangement, expense | $ 6,183,000 | $ 7,363,000 | ||||
Service based-vesting options granted (in shares) | shares | 0 | |||||
Weighted average remaining contractual life (year) | 1 year 9 months 18 days | |||||
Number of peers | peer | 20 | 20 | 20 | |||
Comprehensive loss | $ (10,442,000) | $ (13,569,000) | ||||
Vesting period (year) | 4 years | |||||
Adjustment | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Comprehensive loss | $ (1,600,000) | |||||
Options | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based payment arrangement, expense | $ 0 | |||||
Unrecognized compensation costs for service vesting-based stock options | 0 | |||||
Restricted Stock | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based payment arrangement, expense | 4,700,000 | |||||
Unrecognized compensation costs for service vesting-based stock options | 35,400,000 | |||||
Aggregate fair value of the service vesting-based awards granted | 3,200,000 | |||||
Aggregate fair value of the service vesting-based awards that vested | $ 3,700,000 | |||||
Period for recognition (year) | 2 years 7 months 6 days | |||||
Granted (in shares) | shares | 186,272 | |||||
Grant date fair value (in dollars per share) | $ / shares | $ 17.66 | $ 18.32 | ||||
Vested (in shares) | shares | 221,829 | |||||
Performance Shares | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based payment arrangement, expense | $ 200,000 | |||||
Service based-vesting options granted (in shares) | shares | 0 | |||||
Unrecognized compensation costs for service vesting-based stock options | $ 1,700,000 | |||||
Period for recognition (year) | 1 year 9 months 18 days | |||||
Granted (in shares) | shares | 109,512 | |||||
Grant date fair value (in dollars per share) | $ / shares | $ 17.36 | |||||
Aggregate fair value of the market-based awards granted | $ 1,900,000 | |||||
Vested (in shares) | shares | 0 | |||||
Market-based Restricted Stock | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based payment arrangement, expense | $ 1,100,000 | $ 1,300,000 | ||||
Unrecognized compensation costs for service vesting-based stock options | $ 8,600,000 | |||||
Period for recognition (year) | 1 year 6 months | |||||
Granted (in shares) | shares | 300,529 | 299,565 | ||||
Grant date fair value (in dollars per share) | $ / shares | $ 25.70 | $ 26.50 | ||||
Aggregate fair value of the market-based awards granted | $ 6,300,000 | 6,500,000 | ||||
Vested (in shares) | shares | 300,529 | |||||
Total shareholder return attainment (percent) | 125% | |||||
Historical volatility (percent) | 80% | 78% | 63% | |||
Dividend yield (percent) | 0% | 0% | 0% | |||
Risk-free interest rate | 4.60% | 4.40% | 1.50% | |||
Measurement date with a maturity period (year) | 2 years | 2 years | 2 years | |||
Aggregate fair value of the market-based awards that vested | $ 5,100,000 | $ 700,000 | ||||
Market-based Restricted Stock | Minimum | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Total shareholder return attainment (percent) | 0% | 0% | ||||
Market-based Restricted Stock | Maximum | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Total shareholder return attainment (percent) | 200% | 200% | ||||
Market-based Restricted Stock | Executive Officer | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Share-based payment arrangement, expense | $ 6,300,000 | $ 6,800,000 | $ 6,700,000 | |||
Granted (in shares) | shares | 239,464 | 268,738 | 240,428 |
Stock-based compensation - Sc_2
Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) - $ / shares | 3 Months Ended | |
Mar. 08, 2024 | Mar. 31, 2024 | |
Restricted Stock | ||
Shares | ||
Outstanding as of beginning of period (in shares) | 2,312,898 | |
Granted (in shares) | 186,272 | |
Vested (in shares) | (221,829) | |
Forfeited (in shares) | (51,340) | |
Outstanding as of end of period (in shares) | 2,226,001 | |
Wtd. Avg. Grant Date Fair Value | ||
Outstanding as of beginning of period (in dollars per share) | $ 18.32 | |
Granted (in dollars per share) | 17.36 | |
Vested (in dollars per share) | 24.02 | |
Forfeited (in dollars per share) | 17.69 | |
Outstanding as of end of period (in dollars per share) | $ 17.66 | |
Market-based Restricted Stock | ||
Shares | ||
Outstanding as of beginning of period (in shares) | 509,166 | |
Granted (in shares) | 300,529 | 299,565 |
Vested (in shares) | (300,529) | |
Outstanding as of end of period (in shares) | 508,202 | |
Wtd. Avg. Grant Date Fair Value | ||
Outstanding as of beginning of period (in dollars per share) | $ 26.50 | |
Granted (in dollars per share) | 23.20 | |
Vested (in dollars per share) | 27.97 | |
Outstanding as of end of period (in dollars per share) | $ 25.70 |
Stock-based compensation - Sc_3
Stock-based compensation - Schedule of Stock Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Total | $ 6,183 | $ 7,363 |
Cost of revenue | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Total | 1,120 | 1,631 |
General and administrative costs | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Total | 3,130 | 3,293 |
Sales and marketing costs | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Total | 1,186 | 1,256 |
Research and development costs | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Total | $ 747 | $ 1,183 |
Income taxes (Details)
Income taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | ||
Income tax expense (benefit) | $ 131 | $ 92 |
Effective income tax rate reconciliation, percent | (1.20%) | |
Effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount | $ 600 | |
Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent | (1.80%) | |
Effective income tax rate reconciliation, at federal statutory income tax rate, percent | 21% | |
Deferred tax assets, valuation allowance | $ 54,700 |
Net loss per common share - Sch
Net loss per common share - Schedule of Earnings Per Share, Basic and Diluted, Two Class Method (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Numerator: | ||
Net loss | $ (10,221) | $ (13,714) |
Net loss allocated to common shareholders | (10,221) | (13,714) |
Net loss allocated to common shareholders | $ (10,221) | $ (13,714) |
Denominator: | ||
Weighted average common shares issued, basic (in shares) | 45,432,426 | 43,027,612 |
Weighted average common shares outstanding, basic (in shares) | 45,432,426 | 43,027,612 |
Weighted average common shares issued, diluted (in shares) | 45,432,426 | 43,027,612 |
Weighted average common shares outstanding, diluted (in shares) | 45,432,426 | 43,027,612 |
Loss per common share, basic (in dollars per share) | $ (0.22) | $ (0.32) |
Loss per common share, diluted (in dollars per share) | $ (0.22) | $ (0.32) |
Net loss per common share - S_2
Net loss per common share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 3,766,824 | 3,153,029 |
Stock options and restricted stock awards | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 3,766,824 | 3,153,029 |
Employee benefit plan (Details)
Employee benefit plan (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Retirement Benefits [Abstract] | ||
Defined contribution plan, employer matching contribution, percent of employees' gross pay | 100% | |
Defined contribution plan, employer discretionary contribution amount | $ 0.3 | $ 0.3 |
Subsequent events - Narrative (
Subsequent events - Narrative (Details) - Subsequent Event $ / shares in Units, $ in Thousands | Apr. 17, 2024 USD ($) employee $ / shares |
Global Cooling | |
Subsequent Event [Line Items] | |
Cash required on closing date | $ 7,000 |
Disposal Group, Held-for-Sale, Not Discontinued Operations | Global Cooling | |
Subsequent Event [Line Items] | |
Cash required on closing date, funded by entity | 4,910 |
Repayment of indebtedness | $ 2,596 |
Expected reduction of workforce | employee | 47 |
Expected reduction of workforce (percent) | 11% |
Restructuring charges | $ 1,595 |
Accelerated cost | $ 4,500 |
Period of transition services | 90 days |
Disposal Group, Held-for-Sale, Not Discontinued Operations | Stock Compensation Expense | Global Cooling | |
Subsequent Event [Line Items] | |
Restructuring charges | $ 1,300 |
Disposal Group, Held-for-Sale, Not Discontinued Operations | Cash Expenditures | Global Cooling | |
Subsequent Event [Line Items] | |
Restructuring charges | $ 300 |
Disposal Group, Held-for-Sale, Not Discontinued Operations | GCI Holdings | Global Cooling | |
Subsequent Event [Line Items] | |
Selling price per share (in dollars per share) | $ / shares | $ 1 |
Second Amendment Term Loan | |
Subsequent Event [Line Items] | |
Termination fee, amount | $ 500 |
Financial covenant requirement amount | $ 15,000 |
Subsequent events - Disposal Gr
Subsequent events - Disposal Groups, Including Discontinued Operations (Details) - Subsequent Event - Disposal Group, Held-for-Sale, Not Discontinued Operations $ / shares in Units, $ in Thousands | Apr. 17, 2024 USD ($) $ / shares |
Global Cooling | |
Subsequent Event [Line Items] | |
Selling price: $1 | $ 0 |
Cash to Global Cooling funded by Company | (4,910) |
Approximate costs to sell Global Cooling | (2,409) |
Negative selling price | (7,319) |
Global Cooling carrying basis as of December 31, 2023(2) | (963) |
Estimated net loss on disposal | $ (8,282) |
GCI Holdings | Global Cooling | |
Subsequent Event [Line Items] | |
Selling price per share (in dollars per share) | $ / shares | $ 1 |
Subsequent events - Schedule of
Subsequent events - Schedule of Additional Costs Incurred (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Apr. 17, 2024 | Mar. 31, 2024 | Mar. 31, 2023 | |
Subsequent Event [Line Items] | |||
Global Cooling employee stock based compensation expense | $ 6,183 | $ 7,363 | |
Subsequent Event | Disposal Group, Held-for-Sale, Not Discontinued Operations | Global Cooling | |||
Subsequent Event [Line Items] | |||
Global Cooling Term Notes payoff | $ 2,596 | ||
Assumed liabilities from Global Cooling | 2,353 | ||
RIF compensation expenses | 1,595 | ||
Global Cooling employee stock based compensation expense | 4,106 | ||
Total | 10,650 | ||
Accounts payable | 1,800 | ||
Accrued expenses | 600 | ||
Subsequent Event | Disposal Group, Held-for-Sale, Not Discontinued Operations | Stock Compensation Expense | Global Cooling | |||
Subsequent Event [Line Items] | |||
RIF compensation expenses | 1,300 | ||
Subsequent Event | Disposal Group, Held-for-Sale, Not Discontinued Operations | Cash Expenditures | Global Cooling | |||
Subsequent Event [Line Items] | |||
RIF compensation expenses | $ 300 |